Background Survival of preterm infants has improved drastically. In addition to significant
contribution to neonatal mortality, impact of prematurity among survivors may continue …

Key content: The prevalence of preterm birth is increasing and owing to advances in
neonatal care, more infants are surviving. However, in parallel with this, the incidence of …

Introduction Magnesium sulfate is used world‐wide to treat pregnant women at imminent risk
of preterm delivery in order to protect the brain of the premature infant. Previous research …

The neuro-protective effect of antenatal magnesium sulfate on very preterm infants has been
demonstrated in good-quality randomised controlled trials and meta-analyses. Magnesium …

ContextPrenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very
preterm infants. ObjectiveTo determine the effectiveness of magnesium sulfate given for …

ABSTRACT Background: Magnesium sulfate (MgSO4) can be used for the primary
prevention of cerebral palsy in preterm infants less than 37 weeks of gestational age. Aim …

Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34
weeks' gestation is a major risk factor. Five randomized controlled trials of antenatal …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …